New York, N.Y., USA - January 22, 2015, New York, N.Y., USA - Bristol-Myers Squibb Company announced a number of leadership changes approved by its board of directors and effective at the close of the annual shareholders’ meeting on May 5, 2015.
Article continues below
]
Giovanni Cafori will become chief executive officer of the company.
Mr. Cafori joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. In 2001, he assumed added responsibility for Greece and Israel, and then all of South East Europe in 2003. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization.
In 2007, he was named senior vice president, U.S. Oncology. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president, U.S., in 2011. In 2013, he was named chief commercial officer.
Prior to joining Bristol-Myers Squibb, Mr. Cafori spent 12 years with Abbott Laboratories in a number of leadership positions. Mr. Giovanni received his M.D. from the University of Rome.
Lamberto Andreotti will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3.
Mr. Andreotti joined Bristol-Myers Squibb in 1998 as vice president and general manager, Italy and European Oncology. In 2000, he was named president, Europe. In November 2002, Mr. Andreotti became senior vice president and president, International.
Prior to joining Bristol-Myers Squibb, he held various senior roles at other pharmaceutical companies, including Farmitalia Carlo Erba, KABI Pharmacia and Pharmacia & Upjohn.
Mr. Andreotti earned his bachelor’s degree in engineering from the University of Rome. He obtained a master’s degree from the Massachusetts Institute of Technology.
James M. Cornelius has chosen not to stand for re-election as non-executive chairman and will retire from the board.
Mr. Cornelius has been Bristol-Myers Squibb Non-Executive Chairman since May 2010. He served as Chairman and Chief Executive Officer from February 2008 to May 2010 and served as Chief Executive Officer from September 2006 to February 2008. From November 2005 through April 2006, Mr. Cornelius served as the Chairman of the Board and Chief Executive Officer (interim) of Guidant Corporation, a U.S. cardiac and vascular medical device company.
He served as Guidant’s Non-Executive Chairman of the Board from 2000 until 2005. Mr. Cornelius is the Non-Executive Chairman of the Board of Directors of Mead Johnson Nutrition Company.
Togo D. West, Jr. will become the lead independent director on the company’s board.
Secretary West has been Chairman of TLI Leadership Group, a strategic consulting firm since 2006 and Chairman of Noblis, Inc., a nonprofit science and technology company since 2001. From 2004 to 2006, Secretary West was the Chief Executive Officer of the Joint Center for Political and Economic Studies, a nonprofit research and public policy institution. ■